168 related articles for article (PubMed ID: 24991716)
1. Safety profile of Erwinia asparaginase treatment in adults with newly diagnosed acute lymphoblastic leukemia: a retrospective monocenter study.
Bigliardi S; Morselli M; Potenza L; Coluccio V; Maccaferri M; Paolini A; Colaci E; Fantuzzi V; Faglioni L; Soci F; Nasillo V; Messerotti A; Pedrazzi P; Marietta M; Luppi M; Forghieri F
Leuk Lymphoma; 2015 Mar; 56(3):770-3. PubMed ID: 24991716
[No Abstract] [Full Text] [Related]
2. The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance.
Horvat TZ; Pecoraro JJ; Daley RJ; Buie LW; King AC; Rampal RK; Tallman MS; Park JH; Douer D
Leuk Res; 2016 Nov; 50():17-20. PubMed ID: 27631159
[TBL] [Abstract][Full Text] [Related]
3. Asparaginase Erwinia chrysanthemi (Erwinaze®): a guide to its use in acute lymphoblastic leukemia in the USA.
Keating GM
BioDrugs; 2013 Aug; 27(4):413-8. PubMed ID: 23794007
[TBL] [Abstract][Full Text] [Related]
4. [The feasibility of Erwinia asparaginase for pediatric patients who developed an allergic reaction to E.coli asparaginase during treatment of acute lymphoblastic leukemia].
Takahashi H; Koh K; Kato M; Isobe K; Yasui N; Mori M; Akiyama K; Kikuchi A; Hanada R
Rinsho Ketsueki; 2013 Apr; 54(4):370-7. PubMed ID: 23666219
[TBL] [Abstract][Full Text] [Related]
5. Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia.
Hak LJ; Relling MV; Cheng C; Pei D; Wang B; Sandlund JT; Rubnitz J; Pui CH
Leukemia; 2004 Jun; 18(6):1072-7. PubMed ID: 15057247
[TBL] [Abstract][Full Text] [Related]
6. [Activity of Erwinia-asparaginase after anaphylactic reaction to Peg-asparaginase].
Viña Romero MM; García Gil S; Nazco Casariego GJ; Merino Alonso J; Gutiérrez Nicolás F
An Pediatr (Engl Ed); 2019 Mar; 90(3):187-188. PubMed ID: 29705180
[No Abstract] [Full Text] [Related]
7. Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients.
Wang B; Relling MV; Storm MC; Woo MH; Ribeiro R; Pui CH; Hak LJ
Leukemia; 2003 Aug; 17(8):1583-8. PubMed ID: 12886246
[TBL] [Abstract][Full Text] [Related]
8. Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group.
Salzer WL; Asselin B; Supko JG; Devidas M; Kaiser NA; Plourde P; Winick NJ; Reaman GH; Raetz E; Carroll WL; Hunger SP
Blood; 2013 Jul; 122(4):507-14. PubMed ID: 23741010
[TBL] [Abstract][Full Text] [Related]
9. L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase.
Pieters R; Hunger SP; Boos J; Rizzari C; Silverman L; Baruchel A; Goekbuget N; Schrappe M; Pui CH
Cancer; 2011 Jan; 117(2):238-49. PubMed ID: 20824725
[TBL] [Abstract][Full Text] [Related]
10. Erwinia asparaginase: coming closer to an understanding of its use in pediatric acute lymphoblastic leukemia?
Maloney KW
Pediatr Blood Cancer; 2010 Feb; 54(2):189-90. PubMed ID: 19967774
[No Abstract] [Full Text] [Related]
11. Asparaginase Erwinia chrysanthemi as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia who have developed hypersensitivity to E. coli-derived asparaginase.
Figueiredo L; Cole PD; Drachtman RA
Expert Rev Hematol; 2016 Mar; 9(3):227-34. PubMed ID: 26765930
[TBL] [Abstract][Full Text] [Related]
12. Minimal effects of E. coli and Erwinia asparaginase on the coagulation system in childhood acute lymphoblastic leukemia: a randomized study.
Risseeuw-Appel IM; Dekker I; Hop WC; Hählen K
Med Pediatr Oncol; 1994; 23(4):335-43. PubMed ID: 8058004
[TBL] [Abstract][Full Text] [Related]
13. Effects of Erwinia-asparaginase on the coagulation system.
Carlsson H; Stockelberg D; Tengborn L; Braide I; Carneskog J; Kutti J
Eur J Haematol; 1995 Nov; 55(5):289-93. PubMed ID: 7493674
[TBL] [Abstract][Full Text] [Related]
14. Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL).
Kwok CS; Kham SK; Ariffin H; Lin HP; Quah TC; Yeoh AE
Pediatr Blood Cancer; 2006 Sep; 47(3):299-304. PubMed ID: 16302217
[TBL] [Abstract][Full Text] [Related]
15. Plasma asparaginase activity, asparagine concentration, and toxicity after administration of Erwinia asparaginase in children and young adults with acute lymphoblastic leukemia: Phase I/II clinical trial in Japan.
Ogawa C; Taguchi F; Goto H; Koh K; Tomizawa D; Ohara A; Manabe A
Pediatr Blood Cancer; 2017 Sep; 64(9):. PubMed ID: 28244643
[TBL] [Abstract][Full Text] [Related]
16. Shedding light on the asparaginase galaxy.
Rizzari C
Blood; 2014 Mar; 123(13):1976-8. PubMed ID: 24677398
[TBL] [Abstract][Full Text] [Related]
17. Peg-asparaginase for acute lymphoblastic leukemia.
Rytting M
Expert Opin Biol Ther; 2010 May; 10(5):833-9. PubMed ID: 20345338
[TBL] [Abstract][Full Text] [Related]
18. Erwinia- and E. coli-derived L-asparaginase have similar effects on hemostasis. Pilot study in 10 patients with acute lymphoblastic leukemia.
Castaman G; Rodeghiero F
Haematologica; 1993; 78(6 Suppl 2):57-60. PubMed ID: 8039761
[TBL] [Abstract][Full Text] [Related]
19. Symptomatic severe hypertriglyceridaemia with asparaginase therapy in acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma: is rechallenging safe?
Lashkari HP; Lancaster D; Atra A; Champion MP; Taj MM
Int J Hematol; 2011 Dec; 94(6):571-5. PubMed ID: 22057510
[TBL] [Abstract][Full Text] [Related]
20. A cost-effectiveness analysis of Erwinia asparaginase therapy in children with acute lymphoblastic leukemia.
Kloos RQH; van Litsenburg RRL; Wolf S; Wismans L; Kaspers GJL; Uyl-de Groot CA; Pieters R; van der Sluis IM
Pediatr Blood Cancer; 2019 Jan; 66(1):e27458. PubMed ID: 30246496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
